Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis

Authors

  • Ahmed Elgebaly Faculty of Medicine, Al Azhar University, Cairo, Egypt
  • Ibrahim A. I. Radwan Ain Shams University, Faculty of Medicine, Egypt
  • Mohamed M. AboElnas Kasr-AlAiny Medical School, Cairo University, Cairo, Egypt
  • Hamza H. Ibrahim Faculty of Pharmacy, Alexandria University, Alexandria, Egypt
  • Moutaz F. M. Eltoomy Genetic Engineering & Biotechnology Research Institute, University of Sadat City, Egypt
  • Ahmed A. Atta Faculty of Veterinary Medicine, Cairo University, Cairo, Egypt
  • Hend A. Mesalam Faculty of Medicine, Al Azhar University, Cairo, Egypt
  • Alaa A. Sayed Faculty of Medicine, Beni Suef University, Egypt
  • Amr A. Othman Department of Pharmaceutics and Pharmaceutical Sciences, Faculty of Pharmacy, Alexandria University, Egypt

DOI:

https://doi.org/10.15403/jgld.2014.1121.261.ely

Keywords:

Non-alcoholic fatty liver disease, Resveratrol, steatosis, meta-analysis

Abstract

Background: Resveratrol is a potential treatment option for management of non-alcoholic fatty liver disease (NAFLD) due to its anti-inflammatory, antioxidant properties, and calorie restriction-like effects. We aimed to synthesise evidence from published randomized clinical trials (RCTs) about the efficacy of resveratrol in the management of NAFLD.
Methods: A computer literature search of PubMed, Scopus, Web of Science, and Cochrane Central was conducted using relevant keywords. Records were screened for eligible studies and data were extracted and synthesized using Review Manager Version 5.3 for windows. Subgroup analysis and sensitivity analysis were conducted.
Results: Four RCTs (n=158 patients) were included in the final analysis. The overall effect estimates did not favor resveratrol group in terms of: serum ALT (MD -2.89, 95%CI [-15.66, 9.88], p=0.66), serum AST (MD -3.59, 95%CI [-13.82, 6.63], p=0.49), weight (MD -0.18, 95%CI [-0.92, 0.55], p=0.63), BMI (MD -0.10, 95 %CI [-0.43, 0.24], p=0.57), blood glucose level (MD -0.27, 95%CI [-0.55, 0.01], p=0.05), insulin level (MD -0.12, 95%CI [-0.69, 0.46], p=0.69), triglyceride level (MD 0.04, 95%CI [-0.45, 0.53], p=0.87), and LDL level (MD 0.21, 95%CI [-0.41, 0.83], p=0.51). Pooled studies were heterogeneous.
Conclusion: Current evidence is insufficient to support the efficacy of resveratrol in the management of NAFLD. Resveratrol does not attenuate the degree of liver fibrosis or show a significant decrease in any of its parameters.
Abbreviations: ALT: Alanine aminotransferase; AMPK: AMP-activated protein kinase; AST: Aspartate aminotransferase; BMI: Body mass index; CK-18: Cytokeratin-18; CRP: C-reactive protein; HC: Head circumference; HDL: High density lipoprotein; IL-6: Interleukin-6; LDL: Low density lipoprotein; MD: Mean difference; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; RCT: Randomized Controlled Trial; RR: Relative risk; SIRT1: Silent information regulation 2 homologue 1; TNF-α: Tumor necrosis factor α; WC: Waist circumference; WHR: Waist hip ratio.

March 2017, volume 26, issue 1

Downloads

Published

2017-03-01

How to Cite

1.
Elgebaly A, Radwan IAI, AboElnas MM, Ibrahim HH, Eltoomy MFM, Atta AA, Mesalam HA, Sayed AA, Othman AA. Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis. JGLD [Internet]. 2017 Mar. 1 [cited 2026 Jun. 13];26(1):59-67. Available from: https://jgld.ro/jgld/index.php/jgld/article/view/933

Issue

Vol. 26 No. 1: March 2017

Section

Systematic Review and Meta-Analysis